Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial. (PubMed, Circulation) - Sep 1, 2026 - P3 | "These results support using evolocumab to improve survival in high-risk patients who have not experienced a previous myocardial infarction or stroke, including those with high-risk diabetes without qualifying atherosclerosis with low-density lipoprotein-cholesterol ≥ 90 mg/dl (or non-high-density lipoprotein-cholesterol ≥ 120 mg/dl or apolipoprotein B ≥ 80 mg/dl). URL: https://www.clinicaltrials.gov; Unique identifier: NCT03872401."
Clinical • Journal • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • APOB
|
|
; A Leiter; Ajay K Bhatia; Alexandr Parkhomenko; Andrea Bellavia; Andrejs Erglis; Assen Goudev; Erin A Bohula; Gabriel Paiva da Silva Lima; Gaetano M De Ferrari; Gilles Montalescot; Henrik K Jensen; Huei Wang; Jorge Ferreira; Jose C Nicolau; Lyrica Liu; Marc S Sabatine; Naveed Sattar; Peter Sinnaeve; Rimvydas Slapikas; Róbert Gábor Kiss; Robert P Giugliano; Sabina A Murphy; Vladimír Bláha
|